152 related articles for article (PubMed ID: 33122888)
21. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of a highly sensitive LC-ESI-MS/MS method for estimation of IIIM-MCD-211, a novel nitrofuranyl methyl piperazine derivative with potential activity against tuberculosis: Application to drug development.
Magotra A; Sharma A; Gupta AP; Wazir P; Sharma S; Singh PP; Tikoo MK; Vishwakarma RA; Singh G; Nandi U
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():200-206. PubMed ID: 28623772
[TBL] [Abstract][Full Text] [Related]
23. Rapid LC-MS/MS Bosutinib Quantification with Applications in Metabolic Stability Estimation.
Attwa MW; Alanazi MM
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838629
[TBL] [Abstract][Full Text] [Related]
24. A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation.
Abdelhameed AS; Attwa MW; Al-Shaklia NS; Kadi AA
R Soc Open Sci; 2019 Jun; 6(6):190434. PubMed ID: 31312501
[TBL] [Abstract][Full Text] [Related]
25. A rapid and sensitive LC-MS/MS method for evaluation of the absolute oral bioavailability of a novel c-Met tyrosine kinase inhibitor QBH-196 in rats.
Zhang Q; Sun J; Lu T; Zhang J; Wu C; Li L; He Z; Zhao Y; Liu X
Biomed Chromatogr; 2015 Nov; 29(11):1650-6. PubMed ID: 25880630
[TBL] [Abstract][Full Text] [Related]
26. A highly efficient and sensitive LC-MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study.
Kadi AA; Abdelhameed AS; Darwish HW; Attwa MW; Al-Shakliah NS
Biomed Chromatogr; 2016 Aug; 30(8):1248-55. PubMed ID: 26683307
[TBL] [Abstract][Full Text] [Related]
27. An Ultrafast UPLC-MS/MS Method for Characterizing the In Vitro Metabolic Stability of Acalabrutinib.
Attwa MW; Bakheit AH; Abdelhameed AS; Kadi AA
Molecules; 2023 Oct; 28(20):. PubMed ID: 37894699
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures.
Mooiman KD; Maas-Bakker RF; Rosing H; Beijnen JH; Schellens JH; Meijerman I
Biomed Chromatogr; 2013 Sep; 27(9):1107-16. PubMed ID: 23674377
[TBL] [Abstract][Full Text] [Related]
29. Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry.
Martínez-Chávez A; Rosing H; Hillebrand M; Tibben M; Schinkel AH; Beijnen JH
Anal Bioanal Chem; 2019 Aug; 411(20):5331-5345. PubMed ID: 31209549
[TBL] [Abstract][Full Text] [Related]
30. A quantitative LC-MS/MS method for determination of a small molecule agonist of EphA2 in mouse plasma and brain tissue.
Zhong B; Li Y; Idippily N; Petty A; Su B; Wang B
Biomed Chromatogr; 2019 Apr; 33(4):e4461. PubMed ID: 30548501
[TBL] [Abstract][Full Text] [Related]
31. Liquid chromatography tandem mass spectrometry method for the quantification of vandetanib in human plasma and rat liver microsomes matrices: metabolic stability investigation.
Amer SM; Kadi AA; Darwish HW; Attwa MW
Chem Cent J; 2017 May; 11(1):45. PubMed ID: 29086823
[TBL] [Abstract][Full Text] [Related]
32. Quantitative analysis of PD 0332991 in xenograft mouse tumor tissue by a 96-well supported liquid extraction format and liquid chromatography/mass spectrometry.
Nguyen L; Zhong WZ; Painter CL; Zhang C; Rahavendran SV; Shen Z
J Pharm Biomed Anal; 2010 Nov; 53(3):228-34. PubMed ID: 20236782
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of LC-MS/MS method for determining the metabolic stability, pharmacokinetics, and dose proportionality of a novel anti-inflammatory cofilin inhibitor.
Alsegiani AS; Shah ZA
J Pharm Biomed Anal; 2023 Mar; 226():115258. PubMed ID: 36709658
[TBL] [Abstract][Full Text] [Related]
34. LC-MS/MS method for quantitation of the CK2 inhibitor silmitasertib (CX-4945) in human plasma, CSF, and brain tissue, and application to a clinical pharmacokinetic study in children with brain tumors.
Zhong B; Campagne O; Salloum R; Purzner T; Stewart CF
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Sep; 1152():122254. PubMed ID: 32615532
[TBL] [Abstract][Full Text] [Related]
35. Detection and characterization of olmutinib reactive metabolites by LC-MS/MS: Elucidation of bioactivation pathways.
Attwa MW; Kadi AA; Abdelhameed AS
J Sep Sci; 2020 Feb; 43(4):708-718. PubMed ID: 31788977
[TBL] [Abstract][Full Text] [Related]
36. Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma.
Attwa MW; Kadi AA; Darwish HW; Abdelhameed AS
RSC Adv; 2018 Nov; 8(70):40387-40394. PubMed ID: 35558213
[TBL] [Abstract][Full Text] [Related]
37. Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.
Roche S; McMahon G; Clynes M; O'Connor R
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(31):3982-90. PubMed ID: 19854117
[TBL] [Abstract][Full Text] [Related]
38. Metabolite identification of a new tyrosine kinase inhibitor, HM781-36B, and a pharmacokinetic study by liquid chromatography/tandem mass spectrometry.
Kim E; Kim H; Suh K; Kwon S; Lee G; Park NH; Hong J
Rapid Commun Mass Spectrom; 2013 Jun; 27(11):1183-95. PubMed ID: 23650031
[TBL] [Abstract][Full Text] [Related]
39. A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma.
Svedberg A; Gréen H; Vikström A; Lundeberg J; Vikingsson S
J Pharm Biomed Anal; 2015 Mar; 107():186-95. PubMed ID: 25594896
[TBL] [Abstract][Full Text] [Related]
40. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.
Schittenhelm MM; Kampa KM; Yee KW; Heinrich MC
Cell Cycle; 2009 Aug; 8(16):2621-30. PubMed ID: 19625780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
